Veracyte | VCYT - Cost Of Sales


Veracyte reported $39.28M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Agenus USD 642K 399K Sep/2025
Agilent USD 852M 19M Dec/2025
Anika Therapeutics USD 11.44M 797K Dec/2025
Bruker USD 528M 46.9M Dec/2025
Heron Therapeutics USD 11.12M 795K Dec/2025
Illumina USD 400M 49M Dec/2025
Intrexon USD 1.01M 344K Jun/2024
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
Laboratory Of America USD 2.6B 56.8M Dec/2025
Ligand Pharmaceuticals USD 11.9M 733K Sep/2025
Myriad Genetics USD 63M 1.1M Dec/2025
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Roche Holding CHF 8.48B 4.61B Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Siemens EUR 11.51B 1.82B Dec/2025
Sonic Healthcare AUD 751.66M 801.13M Dec/2024
Thermo Fisher Scientific USD 7.58B 674M Dec/2025
Veracyte USD 39.28M 1.93M Dec/2025
Waters USD 374.94M 47.13M Dec/2025